Decision aids that support decisions about prenatal testing for Down syndrome: an environmental scan by unknown
RESEARCH ARTICLE Open Access
Decision aids that support decisions about
prenatal testing for Down syndrome: an
environmental scan
Maria Esther Leiva Portocarrero1, Mirjam M Garvelink1, Maria Margarita Becerra Perez1, Anik Giguère3,4,
Hubert Robitaille1, Brenda J. Wilson2, François Rousseau5,6 and France Légaré1,4*
Abstract
Background: Prenatal screening tests for Down syndrome (DS) are routine in many developed countries and new
tests are rapidly becoming available. Decisions about prenatal screening are increasingly complex with each
successive test, and pregnant women need information about risks and benefits as well as clarity about their values.
Decision aids (DAs) can help healthcare providers support women in this decision. Using an environmental scan,
we aimed to identify publicly available DAs focusing on prenatal screening/diagnosis for Down syndrome that
provide effective support for decision making.
Methods: Data sources searched were the Decision Aids Library Inventory (DALI) of the Ottawa Patient Decision
Aids Research Group at the Ottawa Health Research Institute; Google searches on the internet; professional
organizations, academic institutions and other experts in the field; and references in existing systematic reviews on
DAs. Eligible DAs targeted pregnant women, focused on prenatal screening and/or diagnosis, applied to tests for
fetal abnormalities or aneuploidies, and were in French, English, Spanish or Portuguese. Pairs of reviewers
independently identified eligible DAs and extracted characteristics including the presence of practical decision
support tools and features to aid comprehension. They then performed quality assessment using the 16 minimum
standards established by the International Patient Decision Aids Standards (IPDASi v4.0).
Results: Of 543 potentially eligible DAs (512 in DALI, 27 from experts, and four on the internet), 23 were eligible
and 20 were available for data extraction. DAs were developed from 1996 to 2013 in six countries (UK, USA, Canada,
Australia, Sweden, and France). Five DAs were for prenatal screening, three for prenatal diagnosis and 12 for both).
Eight contained values clarification methods (personal worksheets). The 20 DAs scored a median of 10/16
(range 6–15) on the 16 IPDAS minimum standards.
Discussion: None of the 20 included DAs met all 16 IPDAS minimum standards, and few included practical
decision support tools or aids to comprehension.
Conclusions: Our results indicate there is a need for DAs that effectively support decision making regarding
prenatal testing for Down syndrome, especially in light of the recently available non-invasive prenatal
screening tests.
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Background
Every year, 447 500 women become pregnant in Canada
[1] and are offered prenatal screening to identify serious
fetal abnormalities as part of the routine pregnancy care
program [2]. The most common fetal anomaly is Down
syndrome (DS) which is caused by a trisomy of chromo-
some 21 (T21) and is characterized by physical problems
(such as head and face anomalies, congenital heart
defects, gastrointestinal malformation, orthopedic abnor-
malities, thyroid dysfunction, diabetes mellitus and hear-
ing loss); and behavioral and cognitive problems
(including cognitive impairment, attention-deficit/hyper-
activity disorder or ADHD), depression, expressive
language deficiency, aggressive behavior, and autism [3].
However studies also indicate that individuals with DS
can have a fulfilling life and enjoy meaningful relation-
ships and that a significant proportion of parents will
choose to pursue a pregnancy with DS [4, 5].
Although all pregnant women are at risk of carrying a
fetus with T21, the risk increases with maternal age or
with a family history of DS [6, 7]. Prenatal testing is
intended to inform women of the risk or presence of
certain genetic conditions. Screening is offered to all
pregnant women to assess their risk of carrying a fetus
with DS, while diagnosis of DS is only offered to women
with a positive screening result (indicating that they have
a high risk of carrying a child with DS)) [6]. For several
years most developed countries have offered both types
of prenatal testing for DS: 1) the combined first-
trimester screen (non-invasive), and 2) prenatal diagno-
sis using amniocentesis or chorionic villus sampling
(CVS) (invasive). The combined first-trimester screen
consists of an ultra-sonographic measurement of nuchal
translucency and maternal serum test which measures
the levels of β-human chorionic gonadotropin and
pregnancy-associated plasma protein A. This test has an
85–90 % detection rate for aneuploidy and a false-
positive rate of 5 % [8]. A new non-invasive prenatal
screening method (NIPT) requires a simple blood sam-
ple from the mother. NIPT uses massive parallel or tar-
geted sequencing of cell-free fetal DNA found in the
maternal blood [9–13] and represents an intermediate
step between serum screening and invasive diagnostic
testing [14]. Although NIPT offers a significant improve-
ment in accuracy, it is not yet offered as a diagnostic
test. With greater than 99 % sensitivity and less than a
1 % false-positive rate, however, once its availability is
widespread fewer follow-up diagnostic tests will be
necessary [8].
Out of 10 000 women who undergo prenatal screen-
ing, approximately 415 receive a positive screening result
and decide to undergo prenatal diagnosis (amniocentesis
or CVS). Of these, 400 will not be carrying a fetus with
T21 [7]. However, they may experience moments of
anxiety while awaiting their test results (approximately
1–2 weeks) and they face a (small) risk of miscarriage
[15]. Indeed, one or two out of the 415 women who
undergo amniocentesis will have a miscarriage which
could involve a healthy fetus [7, 16], and fetal loss rate
for CVS is similar [17–19]. Moreover, DS is not curable,
and the test results of a positive diagnosis entail a diffi-
cult decision about either terminating the pregnancy or
preparing for a high-needs child [20]. Before they reach
this stage, therefore, pregnant women need to receive
clear and accurate information about the implications of
their initial decision about prenatal screening as well as
support for values clarification and decision making
[21]. The decision to undergo the screening test must be
voluntary, well-informed, and congruent with the par-
ents’ values and preferences. Thus, identifying pregnant
women’s perceptions about shared decision making is a
necessary precursor to promoting their active participa-
tion and autonomy in the shared decision making
process in the context of both prenatal screening and
prenatal diagnosis of DS [22].
Research has shown that pregnant women want to be
part of the decision-making process about prenatal tests
[23, 24]. Standard information material such as educa-
tional leaflets help people to understand their diagnosis
and management [25], but in the context of DS this kind
of educational material may not be enough to help preg-
nant women make an informed decision about whether
or not to undergo screening [26]. A study on informa-
tion about DS provided to pregnant women in Canada
based on a content analysis of prenatal screening infor-
mation pamphlets (educational leaflets) concluded that
these pamphlets do not present a comprehensive,
balanced portrayal of DS and thus are not adequate for
supporting shared decision making [27].
Decision aids (DAs) are tools designed to help people
participate in decision making about health care options
by not only providing information on the options but
also by helping them clarify and communicate the per-
sonal values they associate with the different options
[28]. DAs have been found to stimulate people to take a
more active role in decision making, to increase know-
ledge and, when probabilities are included in DAs, to
improve the accuracy of risk perception [29]. A system-
atic review of 115 studies has demonstrated the effect-
iveness of DAs in helping people who are facing
treatment or screening decisions [29]. Another system-
atic review showed that DAs can have a positive effect
on the decision making process in the prenatal context
[25]. More specifically, DAs can significantly decrease
decisional conflict [25], defined as a personal uncertainty
when making a choice between two or more options that
present potential losses or gains, and anticipating poten-
tial regret about forgoing the positive aspects of options
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that were not selected. Decisional conflict is the most
commonly used outcome to assess unresolved decisional
conflict [30, 31].
Decision aids have been shown to increase knowledge
and decrease anxiety with regard to prenatal testing [25].
In addition, provision of detailed information about
prenatal testing has been shown to be significantly
associated with an increase in patient knowledge and
satisfaction [32]. However, not enough studies have
evaluated DAs developed specifically for prenatal test-
ing. In fact, according to a systematic review pub-
lished in 2014 [32], only one study evaluated the
effectiveness of DAs for supporting women’s decision
making about prenatal testing. A review of decision
support technologies for amniocentesis has reported
that there is a need for improvement in high-quality
publicly available decision support tools [33]. In
addition, few new DAs are made publicly available
even after studies have proven their effectiveness [34].
Using an environmental scan, we aimed to identify
publicly available DAs focusing on prenatal screening/
diagnosis for Down syndrome. Then, using IPDAS mini-
mum standards as well as data on practical support and
comprehensibility, we aimed to analyze the extent to
which these DAs could support decision making in the
context of prenatal testing for DS.”
Methods
The 16 Minimum Standards for Certifying Patient Deci-
sion Aids in the refined International Patient Decision
Aids Standards (IPDASi v4.0) represent essential ele-
ments of information that must be present in any DA
[35]. However, they do not indicate the presence of prac-
tical decision support tools, such as methods for evaluat-
ing women’s understanding of the information about the
test and of options and outcomes, or values clarification
methods, both of which are additional important ele-
ments of effective DAs [28, 29]. Values clarification
methods are sections within DAs intended to assist pa-
tients in elucidating their values and preferences about
the options so they can fully integrate the information
and finally make an informed choice that is in accord-
ance with their values and preferences [36]. These
methods consist of worksheets that lead patients
through the three steps (choosing, prizing and acting) of
the values clarification process, [37] and present the op-
tions in a balanced way to help patients weigh their rela-
tive benefits and limitations [36, 38]. In addition, the
minimum standards do not address comprehensibility of
the information, such as visual representations (graphs,
tables, drawings, pictures, organizational charts, algo-
rithms) or educational components (glossary, definitions,
diagrams, abbreviations or explanations, tutorials, links,
flowcharts). Based on the expanded IPDAS checklist for
users [39], we therefore extracted data concerning these
additional components.
An environmental scan (ES) was therefore performed
in order to identify all publicly available DAs that focus
on prenatal screening/diagnosis for DS. The IPDAS
minimum standards and data on their practical and
comprehension features were used to explore the extent
to which these DAs could support decision making.
Environmental scans were developed as tools for re-
trieving and organizing data from a wide variety of fields
in order to identify contexts and shifts in planning for
the future [40]. They can include internal (e.g. memos,
notes from meetings with stakeholders, etc.) as well as
external sources (e.g. newly available technologies) [40].
An environmental scan was appropriate because we
sought to identify as many decision aids in this area as
possible, irrespective of whether or not they had been
the subject of published evaluations. Given that most of
the DAs we identified had not been evaluated, they
would have been missed in a systematic review [40].
DAs developed by our team were considered as an
internal source in addition to DAs developed by other
institutions, thus increasing the number of DAs available
for analysis.
The scan followed the PRISMA flow diagram for
reporting standards in systematic reviews and meta-
analysis [41]. Ethics approval was obtained from the Re-
search Ethics Boards of the Centre de Santé et Services
Sociaux de la Vieille-Capitale (#2013-2014-29) in Quebec,
and the CHU de Quebec (#B14-02-1929) as a part of the
PEGASUS Project.
Data sources and search strategies
Four main data sources were searched: i) The Decision
Aids Library Inventory (DALI) of the Ottawa Patient
Decision Aids Research Group at the Ottawa Research
Institute from September 16, 2013 to April 20, 2014.
The DALI contains an up-to-date overview of freely
available DAs on several health topics that meet a min-
imal set of certification and qualification criteria based
on the IPDASi v4.0 (International Patient Decision Aid
Standards) [35]; ii) from February to May 2014, we used
our research network to contact professional organiza-
tions, academic institutions, and experts in the shared
decision making (SDM) field (email, Facebook group
publications, the shared@each SDM network). Experts
were asked if they had produced DAs on prenatal testing
for DS or if they knew other researchers who may have
done so; iii) from May 26 to June 4 2014, with the help
of Google, electronic databases such as YouTube were
searched using the following search strategies designed
by an information specialist and expert librarian: (decision
aid) and (prenatal screening) and (trisomy 21); (support
tool) and (prenatal screening) and (trisomy 21); (prenatal
Leiva Portocarrero et al. BMC Medical Informatics and Decision Making  (2015) 15:76 Page 3 of 10
screening program) and (trisomy 21); (decision aid) and
(prenatal screening) and (Down syndrome); (support tool)
and (prenatal screening OR prenatal screening program)
and (trisomy 21 OR Down syndrome). The first 150 sites
found with each search strategy were analyzed to see if
they met the eligibility criteria; and finally iv) the refer-
ences in existing systematic reviews on DAs were
reviewed [42]. If DAs were not available, a copy was re-
quested from their developers by email.
Data selection
DAs were included that met the following inclusion
criteria: a) targeted pregnant women, b) focused on
prenatal testing (screening and/or diagnosis), c) applied
to tests for fetal abnormalities or aneuploidies, d) were
in French, English, Spanish or Portuguese.
The age of the DA was not an inclusion criterion
because we wanted to capture the greatest number of
DAs possible, and hypothesized that there were few DAs
to support women in prenatal screening for DS [25].
Furthermore, DA updating is one of the 16 minimum
criteria IPDASi (v4.0) and thus any selection bias was
avoided.
All DAs were screened independently by two reviewers
(MMBP, MELP) to determine if they met these four in-
clusion criteria. Eligibility was determined by consensus
and any discrepancies were discussed with the project
coordinator (HR) and the research team. Kappa coeffi-
cient was computed to measure final agreement among
reviewers on DA selection.
Data extraction
Using a data extraction grid developed by our team
(available from authors), two reviewers (MMBP, MELP)
independently extracted the following characteristics of
the eligible DAs: title; country of origin, language; date
of creation/publication; name of developer, author or
editors; website where it could be accessed; whether it
was freely available; targeted public; types and nature of
the tests included; and genetic abnormalities detected by
the included tests. Features of each DA relevant to prac-
tical decision support and comprehensibility were also
extracted. Second, DAs were independently assessed by
two reviewers using a grid created by our team (available
from authors) based on the IPDAS minimum standards.
Six “qualifying” criteria determine whether the interven-
tion can be considered a DA and 10 “certification”
criteria determine risk of harmful biases [35]. Each item
scored either 0 (criterion not met) or 1 (criterion met).
A total score was obtained by adding up the scores on
all items, and ranged from 0 to 16.
Results of the data extraction were determined by con-
sensus. Any discrepancies were resolved through discus-
sion among reviewers and with the project coordinator
(HR) and the research team. Kappa coefficient was
computed to measure final agreement among reviewers.
Data synthesis and analysis
A narrative synthesis of the data was performed, with
assessments of frequency counts of all characteristics
identified including the presence of practical decision
support tools and comprehension aids. Simple descrip-
tive statistics were used to describe eligible DAs and




Figure 1 illustrates the flow of the DAs selection process.
Out of a total of 537 unique potentially eligible DAs, 23
met the eligibility criteria, 20 of which were available for
data extraction. Kappa coefficient was 1.0. Table 1 shows
the 20 eligible DAs listed in alphabetical order.
Characteristics of DAs
Additional file 1: Table S1 summarizes characteristics of
the DAs retained.
Date, place of origin, cost
The DAs identified were developed between 1996 and
2013 in the United Kingdom (7; 35 %), United States of
America (7; 35 %), Canada (2; 10 %), Australia (2; 10 %),
Sweden (1; 5 %) and France (1; 5 %). Most of the DAs
were in English (17; 85 %). Two DAs (10 %) were not
freely available but could be bought online for £3.60
(Additional file 1: Table S1).
Purpose & target of DAs
Five DAs (25 %) were for prenatal screening only, three
(15 %) for prenatal diagnosis and 12 (60 %) for both.
The prenatal screening tests included in the DAs (not
mutually exclusive) were: ultrasound scan (14; 70 %),
maternal serum (12; 60 %), nuchal translucency (11;
55 %) and Non-Invasive Prenatal Testing (NIPT) (1;
5 %). All 20 DAs targeted pregnant women, five DAs
also targeted their partners, and two also targeted
healthcare professionals (Additional file 1: Table S1).
Practical tools for decision support
One DA provided a content summary (5 %); eight (40 %)
included values clarification methods; and five (25 %)
provided a method for evaluating women’s understanding
of the information provided (about the test, the options
and/or of the outcomes) (Additional file 1: Table S1).
Overall, a median of 8/20 provided practical decision
support methods (personal worksheets).
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Content comprehensibility
All DAs provided some kind of visual representation.
DAs used graphs (5; 25 %), tables (14; 70 %), drawings
(7; 35 %), pictures (11; 55 %), organizational charts (1;
5 %) or algorithms that clearly showed the steps of the
decision process (1; 5 %). All DAs provided some kind
of educational component, including important defini-
tions (17; 85 %), a glossary (1; 5 %), a diagram (1; 5 %),
explanations and/or abbreviations (8; 40 %), links to
more information (14; 70 %) or a flowchart of the
decision making process (1; 5 %).
IPDAS minimum standards
With regard to our IPDAS “qualifying” criteria (Table 2),
all 20 DAs (100 %) explicitly stated the index decision
and 17 (85 %) described the health condition or problem
for which the index decision was required. Sixteen
(80 %) described the options available for the index deci-
sion, among which eight (40 %) described both the posi-
tive and the negative features of each option (to do or not
to do the test). With regard to “certification” criteria, all
20 DAs (100 %) described what the prenatal test was
designed to measure. Half of the DAs (50 %) provided
information about an update policy, and eight (40 %) (not
mutually exclusive) showed the negative and positive
features of options in equal detail (using similar fonts,
sequence, and representation of statistical information).
None of the 20 identified DAs met all minimum stan-
dards. The median score on the 16 Minimum Standards
for Certifying Patient Decision Aids in the refined Inter-
national Patient Decision Aids Standard (IPDASi v4.0)
for the 20 DAs was 10 out of 16 points (range 6–15).
Kappa coefficient was 1.0.
Discussion
We conducted an environmental scan to identify exist-
ing DAs focusing on prenatal testing for DS that could
support decision making about taking or not taking the
test. We identified 23 DAs of which 20 were available
for data extraction. They were produced between 1996
and 2013, in six countries and in three languages. The
principal disorder targeted by all the identified DAs was
DS. Seventeen DAs were for prenatal screening, either
solely or in combination with prenatal diagnosis, and
three were for prenatal diagnosis only. Very few eligible
DAs targeted a spouse or partner or supported a conver-
sation with a provider. Few contained practical decision
support tools and none fulfilled all the IPDAS minimum
standards criteria. The median for the 20 DAs appraised
Fig. 1 Flow diagram of decision aid selection. Criteria 1: DA targets pregnant women; Criteria 2: DA focuses on prenatal testing (screening and/or
diagnosis); Criteria 3: DA applies to tests for fetal abnormalities or aneuploidies; Criteria 4: DA in French, English, Spanish or Portuguese
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was 10 out of 16 points. Our results lead us to make
four main observations.
First, the aim of DAs in the context of prenatal testing
is to help pregnant women make values-sensitive deci-
sions involving not only their own health, but also the
health of their fetus. DAs should provide unbiased nondi-
rective scientific information on the risk and benefits of all
options, and assist pregnant women in clarifying their
personal values concerning outcomes and adverse effects
[25, 39, 43]. At the moment DAs are not achieving this
purpose. Although DALI considers all the tools in its
library as DAs, based on our scoring using the IPDAS
there is large variation in quality across the included DAs
whether they are listed in DALI or not. In addition,
although the available DAs contained some of the infor-
mation necessary for SDM, our analysis showed that few
contained the tools necessary for putting it into practice.
The majority mentioned that pregnant women’s personal
values were important for decision making, but less than
half helped the women express their uncertainties about
the available options by providing a values clarification
instrument, or provided a tool for assessing their under-
standing. In addition, only one DA has been evaluated for
its effectiveness in fostering SDM in practice [44].
Second, although the DAs in this study were all avail-
able, some were difficult to obtain. Moreover, we have
Table 1 DAs that met eligibility criteria
Title Developer Year of publication Source




2004 DALI - Ottawa Research Institute
b Amniocentesis Option Grid Collaborative,
Dartmouth, USA




University of Cardiff, Wales, UK.
2008 DALI - Ottawa Research Institute
d Antenatal Down Syndrome
Screening (VIMEO)
Department of Obstetrics
and Gynecology, Stockholm, Sweden.
2011 DALI - Ottawa Research Institute
e Choices about first trimester
ultrasound scans: A decision aid
for pregnant women
Queensland Centre for Mothers
& Babies - University of Queensland,
Australia
2010 Google
f Do I want a screening test for
Down syndrome
The Newcastle upon Tyne Hospitals
NHS, UK
2013 SDM Organisations
g Down Syndrome Screening Option Grid Collaborative, Dartmouth, USA 2013 DALI - Ottawa Research Institute
h Information destinée aux femmes
enceintes sur la possibilité de
recourir’a leur demande au dépistage
prénatal de la trisomie 21
Collège national des gynécologues
et obstétriciens français, France
2012 Google
i Is my baby alright Midwives Information and
Resource Service, UK
1997 DALI - Ottawa Research Institute
j Making choices: Prenatal Testing Ottawa Patient Decision Aid
Research Group, Canada
1999 DALI - Ottawa Research Institute
k Pour les femmes et leurs familles.
Un guide pour mieux comprendre
les tests de dépistage prénatal
Mount Sinai Hospital, Toronto, Canada 2007 SDM Experts
l Pregnancy - should I have screening
tests for birth defects?
Healthwise, USA 2013 DALI - Ottawa Research Institute
m Pregnancy - should I have CVS? Healthwise, USA 2012 DALI - Ottawa Research Institute
n Pregnancy, should I have amniocentesis? Healthwise, USA 2012 DALI - Ottawa Research Institute
o Pregnancy - should I have an
early fetal ultrasound?
Healthwise, USA 2012 DALI - Ottawa Research Institute
p Prenatal diagnosis for Down Syndrome University of Leeds, UK 2004 DALI - Ottawa Research Institute
q Prenatal Screening - Is it Right for You? Dartmouth - Hitchcock, USA 2013 SDM Experts
r Prenatal Screening Video Michigan State University, USA 2007 YouTube
s The California Prenatal Screening Program California Department of Public
Health - Genetic Disease Screening
Program - Prenatal Screening Program, USA
2013 Google
t Ultrasounds scans - What you need to know Midwives Information and Resource
Service, UK
2008 DALI - Ottawa Research Institute
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Table 2 Quality assessment of DAs (n = 20) according to the IPDASi v4 criteria






Information 1 DA describes health condition or
problem for which index decision is
required
X X X X X X X X X X X X X X X X X 17
2 DA explicitly states the decision that
needs to be considered (index
decision)
X X X X X X X X X X X X X X X X X X X X 20
3 DA describes the options available for
the index decision
X X X X X X X X X X X X X X X X 16
4 DA describes the positive features
(benefits/advantages) of each option
X X X X X X X X 8
5 DA describes the negative features
(harms, side effects, or disadvantages)
of each option
X X X X X X X X X X 10
Values 6 DA describes what it is like to
experience the consequences of the
options (physical, psychological, social)
X X X X X X X X X X X X X X 14
Certification criteria
Information 7 DA shows the negative and positive
features of options in equal detail
(using similar fonts, sequence, and
representation of statistical
information)
X X X X X X X X 8
Evidence 8 DA (or associated documentation)
provides citations to the evidence
selected
X X X X X X X X X 9
9 DA (or associated documentation)
provides a production or a publication
date
X X X X X X X X X X X X X X 14
10 DA (or associated documentation)
provides information about the
update policy
X X X X X X X X X X 10
11 DA provides information about the
levels of uncertainty around event or
outcome probabilities
X X X X X X X X
X
X X X X X
X X
X X X 19
Disclosure 12 DA (or associated documentation)
provides information about the
funding source used for development
X X X X X X X X X X 10
Test 13 DA describes what the test is
designed to measure
X X X X X X X X X X X X X X X X X X X X 20
14 DA describes the next steps typically
taken if the test detects the condition
or problem
X X X X X X X X X X X X X X X X X X X 19
15 DA describes the next steps if the
condition or problem is not detected
X X X X 4
16 DA has information about the
consequences of detecting the
condition or disease that would never
have occurred if screening had not
been done (lead time bias)
X X 2
Total quality score (out of 16)a 13 11 10 9 6 10 10 6 10 11 8 14 13 13 15 12 7 7 6 9
aminumum-maximum scores ranges from 0 to 16
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no data with regard to the frequency with which they
are actually used in practice. Indeed, studies show that
numerous DAs have been developed and evaluated but
not made publicly available afterwards. Although these
DAs were not the focus of this study, this failure to
reach the public should receive adequate attention in
future studies [34]. This highlights the need to pay close
attention to implementation strategies in the develop-
ment of any new DA about prenatal testing [45].
Third, all the DAs we found were produced after 1996,
which is in keeping with the period in which prenatal
tests became available [46]. However, of the 20 DAs in-
cluded in our study, 11 (55 %) were produced after 2011.
As the 16 IPDASi(v4.0) minimum criteria [35] were only
established in 2012, these minimum criteria may not
have been used as a development guide, although the 47
IPDASi(v3.0) criteria [47] established in 2008 included
the 16 minimum criteria. This leads us to believe that
DA authors post-2008 were either not aware of IPDAS
at all, as this is a young field, or did not use the criteria
effectively.
Fourth, interestingly, many DAs were developed in the
same country, language and period. In the United States,
for example, six prenatal testing DAs were published
between 2012 and 2013 and in the United Kingdom
three were published in the same period. On the one
hand their development coincides with the availability of
prenatal testing in their respective healthcare systems,
but their number also illustrates a lack of internal collabor-
ation on development of important patient resources. Fu-
ture studies should emphasize collaborative development of
publicly available patient information and decision support,
thereby focusing scarce resources on supporting pregnant
women in making these difficult decisions instead of on
choosing which of several available DAs to use.
These results should be interpreted with caution due
to some limitations [40]. The search strategy was limited
to four main sources: the Decision Aids Library Inventory,
SDM experts, Google and the references in existing sys-
tematic reviews on DAs. As the focus was only on DAs
available to the general public, some may have been
missed. For example, developmental or evaluation studies
that publish quality assessment data on DAs that are not
publicly available were not searched. Data was restricted
to publicly available DAs since these are what the client
will see and use, and are thus the most relevant to sup-
porting informed decision making in practice today.
Hence, although the four data sources did not permit the
capture of tools not explicitly labelled “decision aids”, they
did allow capture of the majority of existing too.
Conclusion
According to one systematic review, the number of preg-
nant women who undergo prenatal screening is slightly
higher among women informed with DAs, so they do
have some impact on informed choice in pregnancy care
[25]. Nevertheless, according to the results of our ana-
lysis of DAs, at this point in time none of them offer
proper support to pregnant women in decision making
about prenatal screening/diagnosis for DS. The quality
of identified DAs did not meet the IPDAS minimum
standards, and few contained the tools needed to sup-
port informed decision making in practice. We therefore
recommend that DAs for prenatal testing that consider
the 16 minimal standards recommended by the IPDAS,
ensure comprehensibility and contain practical decision
support tools. In addition, attention should be paid to
current developments in prenatal testing techniques,
such as non-invasive prenatal testing (NIPT), which was
addressed in one DA only.
We consider that our study will contribute to the
development of higher-quality decision support tools in
the future, as well as to the implementation of shared
decision making in the context of the sensitive decisions
about prenatal screening for DS.
Based on the outcomes of this study we are currently
developing a DA to support the decision about prenatal
testing for DS. The next phase in its development will
be its evaluation among women facing this decision.
Additional file
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kb)
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